



Department
of Health

Medicaid NYRx

NYRx Education & Outreach MCO Newsletter

[Highlights](#) | [Publications](#) | [Quicklinks](#) | [About](#) | [Weekly Webinars](#) | [Contact](#)

July 2026

Highlights

Ballroom and House Community Crystal Methamphetamine Awareness Campaign

The **Ballroom and House Community Crystal Methamphetamine Awareness Campaign** highlights culturally competent education, harm reduction strategies, mental health support, and community-based services. **Ballroom, We Care** offers a comprehensive three-hour Crystal Meth training program, available both in person and virtually, and a warm invitation is extended to organizations and agencies that serve the community, as well as to community members who may be grappling with Meth-related issues.

- The campaign envisions a significant reduction or elimination of substance use within the Ballroom Scene, thereby significantly reducing deaths related to substance use.
- MCOs are encouraged to share these resources with members and community partners.
- Outreach ranges from volunteer opportunities to sponsorship.



For further information, refer to the [Ballroom and House Community Crystal Methamphetamine Awareness Campaign](#) or contact **Ballroom, We Care Inc.** at contact@ballroomwecare.org.



[Top ↑](#)

NYRx Notice to Providers: Dexcom G6 Continuous Glucose Monitor (CGM) Systems

What Pharmacy Providers and Prescribers Need to Know

Reminder: the manufacturer of Dexcom G6 discontinued the Dexcom G6 CGM system effective July 1, 2026. MCOs can help prepare providers to transition members to alternative devices. Providers should be aware of the new prescription and prior authorization (PA) requirements to prevent interruption in care.

Previously approved PAs of the discontinued Dexcom G6 Sensors may be impacted and will require a new PA.



Patients must receive new prescriptions for either the Dexcom G7 or the Dexcom G7 15-day CGM system.

- For a complete list of Continuous Glucose Monitors covered by NYRx, see the [NYRx Preferred Diabetic Supply Program Resource](#).
- For more information, see [NYRx Notice to Providers: Dexcom G6 Continuous Glucose Monitor \(CGM\) Systems](#).

For further information, see the [NYRx Notice to Providers: Dexcom G6 Continuous Glucose Monitor \(CGM\) Systems](#).



[Top ↑](#)

NYRx, the Medicaid Pharmacy Program: Prior Authorization Update



On **February 26, 2026**, the New York State Medicaid Drug Utilization Review Board (DURB) recommended changes to NYRx, the Medicaid Pharmacy Program. The Commissioner of Health reviewed the DURB's recommendations and approved the following changes.

Effective **July 16, 2026**, the Drug Utilization Review (DUR) program clinical criteria requirements have been implemented.

- Topical Immunomodulators for the treatment of atopic dermatitis:
 - Trial of a medium, high, or very high potency preferred topical corticosteroid.
 - PA is required when a topical Janus kinase inhibitor and systemic immunomodulator are used concurrently.
 - Quantity limits on Ruxolitinib (60 grams/month and 120 grams/year) and Delgocitinib (30 grams/month and 60 grams/year).
- Systemic Immunomodulators for the treatment of atopic dermatitis:
 - Trial of a medium, high, or very high potency preferred topical corticosteroid or a preferred topical immunomodulator.
 - Systemic Janus kinase inhibitors: Trial of a medium, high, or very high potency preferred topical corticosteroid and a preferred systemic immunomodulator.
- Doxepin Cream:
 - Trial of a preferred topical corticosteroid or preferred topical immunomodulator.
 - Quantity limits of 45 grams/month and 180 grams/year.
- Topical Steroids:
 - Low, medium, and high potency topical corticosteroids: a yearly limit of 12 claims, or 360 grams.
 - Very high potency topical corticosteroids: a yearly limit of six claims, or 240 grams.
 - Very high potency topical corticosteroids: an age edit to allow coverage for patients 12 years of age and older.
- Neurokinin Receptor Antagonists:
 - Trial of one hormone replacement therapy regimen, unless otherwise contraindicated.

For more information, see the [NYRx, the Medicaid Pharmacy Program: Prior Authorization Update](#).



NYRx Formulary Update: Prenatal Vitamins

Effective June 4, 2026, NYRx, the Medicaid Pharmacy Program, updated prenatal vitamin coverage.

Pharmacy providers and **prescribers** should work collaboratively to ensure that New York Medicaid members are able to receive their prescribed prenatal supplements. Pharmacy providers should consider submitting claims for prenatal vitamins that do not require PA.

Prescribing **covered formulary options** for prenatal vitamins:

- Do not require PA.
- Allows for up to a 90-day supply.
- Supports care coordination.
- Minimizes delays in member access to prenatal supplements.



What Managed Care Organizations (MCOs) Need to Do

MCOs should review prenatal vitamin utilization for New York Medicaid members to identify use of products not included in the list of reimbursable drugs and complete care coordination activities to prevent any delay in care.

For a list of covered Prenatal Vitamins, see the [NYRx Formulary Update: Prenatal Vitamins](#).



[Top ↑](#)

Publications

Click to access [NYRx, the Medicaid Pharmacy Program](#) website for these publications and more:

- Billing & Coordination of Benefits
- Drug Class Coverage Overviews
- Newsletters
- Notifications
- Prior Authorization Information

[Top ↑](#)

Quicklinks



[NYRx Preferred Drug List](#)



[NYRx Preferred Drug Quick List](#)



[NYRx eMedNY Formulary File](#)



[NYRx Brand Less Than Generic Program Updates](#)



[NYRx Preferred Diabetic Supply Program](#)

[Top ↑](#)

About the NYRx E&O Team

The NYRx E&O team serves as a liaison between all stakeholders and NYRx to support care coordination. Clinical liaisons are trained to support and help solve complex pharmacy cases for:



- Managed Care Plans
- Case workers and NYS agencies
- Prescribers and pharmacies with questions regarding NYRx drug coverage, prior approval requirements, and NYRx enrolled pharmacies
- Complex care coordination for populations such as HIV/AIDS, Hemophilia, Foster Care Children, Serious Mental Illness, Substance Use Disorder, and Hepatitis C

[Top ↑](#)

Weekly Webinars

To register, please visit the [NYRx Education & Outreach](#) website.

Prescriber Webinar

Mondays

12 PM – 1 PM ET

Pharmacy Webinar

Wednesdays

12 PM – 1 PM ET

NYRx, the Medicaid Pharmacy Program

Fridays

12 PM – 1 PM ET

[Top ↑](#)

Contact Us

Office Hour Q&A Pop-In

Mondays and Wednesdays

12 PM – 1 PM ET

[Click here to join.](#)



Meet with the Team

The NYRx E&O team meets with various stakeholders throughout the month. Would you like to request a meeting with us? Click [here](#).

NYRx E&O Call Center

1-833-967-7310

Monday – Friday

8 AM – 5 PM ET

Excludes Holidays



[Top ↑](#)



[Website](#)



[Email](#)



[NYRx E&O Channel](#)



[NYS Public Health Now Podcast](#)